189 related articles for article (PubMed ID: 34987744)
1. Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias.
Al-Samkari H; van Beers EJ
Ther Adv Hematol; 2021; 12():20406207211066070. PubMed ID: 34987744
[TBL] [Abstract][Full Text] [Related]
2. Mitapivat for sickle cell disease and thalassemia.
Pilo F; Angelucci E
Drugs Today (Barc); 2023 Mar; 59(3):125-134. PubMed ID: 36847623
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.
Song AB; Al-Samkari H
Expert Rev Hematol; 2022 Oct; 15(10):875-885. PubMed ID: 36124781
[TBL] [Abstract][Full Text] [Related]
4. Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.
Wills J; Horenstein M; Kim A; Silva MA; Dima L
Am J Ther; 2023 Sep-Oct 01; 30(5):e433-e438. PubMed ID: 37713687
[TBL] [Abstract][Full Text] [Related]
5. Mitapivat: A Novel Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency.
De SK
Curr Med Chem; 2024; 31(6):683-687. PubMed ID: 37125655
[TBL] [Abstract][Full Text] [Related]
6. Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults.
Zhuang-Yan A; Shirley M
Drugs; 2023 Nov; 83(17):1613-1620. PubMed ID: 37991635
[TBL] [Abstract][Full Text] [Related]
7. Mitapivat versus Placebo for Pyruvate Kinase Deficiency.
Al-Samkari H; Galactéros F; Glenthøj A; Rothman JA; Andres O; Grace RF; Morado-Arias M; Layton DM; Onodera K; Verhovsek M; Barcellini W; Chonat S; Judge MP; Zagadailov E; Xu R; Hawkins P; Beynon V; Gheuens S; van Beers EJ;
N Engl J Med; 2022 Apr; 386(15):1432-1442. PubMed ID: 35417638
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease.
Xu JZ; Conrey A; Frey I; Gwaabe E; Menapace LA; Tumburu L; Lundt M; Lequang T; Li Q; Glass K; Dunkelberger EB; Iyer V; Mangus H; Kung C; Dang L; Kosinski PA; Hawkins P; Jeffries N; Eaton WA; Lay Thein S
Blood; 2022 Nov; 140(19):2053-2062. PubMed ID: 35576529
[TBL] [Abstract][Full Text] [Related]
9. Erythrocyte pyruvate kinase activation in red cell disorders.
Matte A; Federti E; De Franceschi L
Curr Opin Hematol; 2023 May; 30(3):93-98. PubMed ID: 36853806
[TBL] [Abstract][Full Text] [Related]
10. Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial.
Glenthøj A; van Beers EJ; Al-Samkari H; Viprakasit V; Kuo KHM; Galactéros F; Chonat S; Porter J; Zagadailov E; Xu R; Oluyadi A; Hawkins P; Gheuens S; Beynon V; Barcellini W;
Lancet Haematol; 2022 Oct; 9(10):e724-e732. PubMed ID: 35988546
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.
Grace RF; Rose C; Layton DM; Galactéros F; Barcellini W; Morton DH; van Beers EJ; Yaish H; Ravindranath Y; Kuo KHM; Sheth S; Kwiatkowski JL; Barbier AJ; Bodie S; Silver B; Hua L; Kung C; Hawkins P; Jouvin MH; Bowden C; Glader B
N Engl J Med; 2019 Sep; 381(10):933-944. PubMed ID: 31483964
[TBL] [Abstract][Full Text] [Related]
12. The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model.
Matte A; Federti E; Kung C; Kosinski PA; Narayanaswamy R; Russo R; Federico G; Carlomagno F; Desbats MA; Salviati L; Leboeuf C; Valenti MT; Turrini F; Janin A; Yu S; Beneduce E; Ronseaux S; Iatcenko I; Dang L; Ganz T; Jung CL; Iolascon A; Brugnara C; De Franceschi L
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33822774
[TBL] [Abstract][Full Text] [Related]
13. Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model.
Quezado ZMN; Kamimura S; Smith M; Wang X; Heaven MR; Jana S; Vogel S; Zerfas P; Combs CA; Almeida LEF; Li Q; Quezado M; Horkayne-Szakaly I; Kosinski PA; Yu S; Kapadnis U; Kung C; Dang L; Wakim P; Eaton WA; Alayash AI; Thein SL
Blood Cells Mol Dis; 2022 Jul; 95():102660. PubMed ID: 35366607
[TBL] [Abstract][Full Text] [Related]
14. An innovative phase I study in healthy subjects to determine the mass balance, elimination, metabolism, and absolute bioavailability of mitapivat.
Prakash C; Mangus H; Yan Y; Yang H; Iyer V
Clin Transl Sci; 2023 Oct; 16(10):2021-2032. PubMed ID: 37596712
[TBL] [Abstract][Full Text] [Related]
15. Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency.
van Beers EJ; Al-Samkari H; Grace RF; Barcellini W; Glenthøj A; DiBacco M; Wind-Rotolo M; Xu R; Beynon V; Patel P; Porter JB; Kuo KHM
Blood Adv; 2024 Feb; ():. PubMed ID: 38330179
[TBL] [Abstract][Full Text] [Related]
16. One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study.
van Dijk MJ; Rab MAE; van Oirschot BA; Bos J; Derichs C; Rijneveld AW; Cnossen MH; Nur E; Biemond BJ; Bartels M; Jans JJM; van Solinge WW; Schutgens REG; van Wijk R; van Beers EJ
Blood Adv; 2023 Dec; 7(24):7539-7550. PubMed ID: 37934880
[TBL] [Abstract][Full Text] [Related]
17. Mitapivat-Associated Rib Fracture in a Hemolytic Anemia Patient.
Abouelkheer Y; Ladel L; Boxer D; Shafique S
Cureus; 2024 Mar; 16(3):e55658. PubMed ID: 38586665
[TBL] [Abstract][Full Text] [Related]
18. Mitapivat reprograms the RBC metabolome and improves anemia in a mouse model of hereditary spherocytosis.
Matte A; Wilson AB; Gevi F; Federti E; Recchiuti A; Ferri G; Brunati AM; Pagano MA; Russo R; Leboeuf C; Janin A; Timperio AM; Iolascon A; Gremese E; Dang L; Mohandas N; Brugnara C; De Franceschi L
JCI Insight; 2023 Oct; 8(20):. PubMed ID: 37676741
[TBL] [Abstract][Full Text] [Related]
19. Pyruvate kinase activators for treatment of pyruvate kinase deficiency.
Grace RF
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):97-106. PubMed ID: 38066940
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study.
Kuo KHM; Layton DM; Lal A; Al-Samkari H; Bhatia J; Kosinski PA; Tong B; Lynch M; Uhlig K; Vichinsky EP
Lancet; 2022 Aug; 400(10351):493-501. PubMed ID: 35964609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
